ESCITALOPRAM OXALATE

Post-LOE

escitalopram oxalate

Aurobindo Pharma

ANDAORALTABLET

Approved

Sep 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ESCITALOPRAM OXALATE (escitalopram oxalate) by Aurobindo Pharma is escitalopram, the s-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for anxiety. First approved in 2012.

Drug data last refreshed 21h ago

Mechanism of Action

escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).

Indications (1)

anxiety

Clinical Trials (1)

NCT02191397Phase 3Completed

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

Started Feb 2015

534 enrolled

Depressive Disorder, Major

Company

Worked on ESCITALOPRAM OXALATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.